CASI Pharmaceuticals (CASIF) granted over RMB 100M in Juventas arbitration
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, reported receiving the final award in its arbitration against Juventas Co., Ltd. before the Hong Kong International Arbitration Centre. The tribunal rejected all of Juventas’s breach allegations and determined that Juventas wrongfully terminated the parties’ CNCT-19 commercialization agreements in March 2024.
The tribunal awarded CASI its wasted costs, interest accruing from the date of Juventas’s wrongful termination, CASI’s share of the arbitral tribunal and HKIAC costs, and a substantial portion of its legal costs, totaling well over RMB 100 million. This information is incorporated by reference into CASI’s existing Registration Statements on Form F-3.
Positive
- Final arbitration win with substantial monetary award: The HKIAC tribunal rejected all breach claims by Juventas, found Juventas wrongfully terminated CNCT-19 agreements, and granted CASI total compensation well over RMB 100 million, including wasted costs, interest, tribunal/HKIAC costs and a substantial portion of legal fees.
Negative
- None.
Key Figures
Arbitration award total: well over RMB 100 million
Wrongful termination date: March 2024
Report signature date: July 15, 2026
3 metrics
Arbitration award total
well over RMB 100 million
Total of wasted costs, interest, tribunal and HKIAC costs, and substantial legal costs awarded to CASI
Wrongful termination date
March 2024
Month and year of Juventas’s wrongful termination of CNCT-19 agreements as referenced in the award
Report signature date
July 15, 2026
Date the report was signed by CASI’s Chairman of the Board
Key Terms
arbitral tribunal, Hong Kong International Arbitration Centre, wasted costs, Registration Statements on Form F-3, +1 more
5 terms
arbitral tribunal regulatory
"reported the receipt of the final award issued by the arbitral tribunal"
An arbitral tribunal is a small panel of neutral decision‑makers chosen to resolve a legal dispute outside the public court system—think of it as a private court or referee picked by the parties. Its decisions are usually final and enforceable, often across borders, so the tribunal’s process, speed, cost and likely outcome matter to investors because they can directly affect the enforceability of contracts, the timing and size of recoveries, and the financial risk tied to a company or investment.
Hong Kong International Arbitration Centre regulatory
"arbitration proceeding against Juventas Co., Ltd. before the Hong Kong International Arbitration Centre"
wasted costs financial
"the tribunal awarded the Company all of its resulting wasted costs, interest accruing"
Registration Statements on Form F-3 regulatory
"incorporated by reference into the Company's Registration Statements on Form F-3"
Private Securities Litigation Reform Act of 1995 regulatory
"made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"
FAQ
What did CASI Pharmaceuticals (CASIF) disclose in its July 2026 report?
CASI Pharmaceuticals disclosed a final arbitration award from the HKIAC against Juventas Co., Ltd. The tribunal rejected all breach allegations against CASI, found Juventas wrongfully terminated CNCT-19 commercialization agreements, and granted CASI compensation totaling well over RMB 100 million.
How much did CASI Pharmaceuticals (CASIF) receive in the Juventas arbitration?
The tribunal awarded CASI total compensation of well over RMB 100 million. This amount covers CASI’s wasted costs, interest accruing from Juventas’s wrongful termination date, its share of arbitral tribunal and HKIAC costs, and a substantial portion of CASI’s legal expenses incurred in pursuing the arbitration.
What was the dispute between CASI Pharmaceuticals (CASIF) and Juventas about?
The dispute concerned Juventas’s purported March 2024 termination of agreements with CASI for commercializing CNCT-19. Juventas claimed CASI breached the agreements. The tribunal rejected these claims and determined Juventas wrongfully terminated the CNCT-19 commercialization agreements with CASI.
Which forum handled CASI Pharmaceuticals’ (CASIF) arbitration with Juventas?
The case was heard before the Hong Kong International Arbitration Centre (HKIAC). An arbitral tribunal constituted under the HKIAC issued the final award, rejecting Juventas’s breach allegations and granting CASI extensive monetary relief related to the CNCT-19 commercialization dispute.
How does this arbitration award affect CASI Pharmaceuticals’ (CASIF) SEC registrations?
The information in this report is incorporated by reference into CASI’s Registration Statements on Form F-3, File Nos. 333-283998 and 333-281621. This means the details of the arbitration award become part of those shelf registration statements for disclosure purposes.
What types of costs did CASI Pharmaceuticals (CASIF) recover from Juventas?
CASI recovered wasted costs, interest from the wrongful termination date, its share of arbitral tribunal and HKIAC costs, and a substantial portion of its legal fees. Together, these components total well over RMB 100 million as awarded by the tribunal.